Invention Grant
- Patent Title: Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
- Patent Title (中): 化疗药物与TGF-β系统抑制剂的组合
-
Application No.: US13059623Application Date: 2010-07-30
-
Publication No.: US08476246B2Publication Date: 2013-07-02
- Inventor: Karl-Hermann Schlingensiepen , Frank Jaschinski , Tanja Rothammer-Hampl , Anneliese Schneider
- Applicant: Karl-Hermann Schlingensiepen , Frank Jaschinski , Tanja Rothammer-Hampl , Anneliese Schneider
- Applicant Address: DE Regensburg
- Assignee: Antisense Pharma GmbH
- Current Assignee: Antisense Pharma GmbH
- Current Assignee Address: DE Regensburg
- Agency: Morrison & Foerster LLP
- Priority: EP09166893 20090730
- International Application: PCT/EP2010/061152 WO 20100730
- International Announcement: WO2011/012713 WO 20110203
- Main IPC: A01N43/04
- IPC: A01N43/04 ; C12N15/63 ; C12Q1/68 ; C07H21/02 ; C07H21/04
Abstract:
Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.
Public/Granted literature
- US20120027873A1 COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN INHIBITOR OF THE TGF-BETA SYSTEM Public/Granted day:2012-02-02
Information query
IPC分类:
